April 8, 2020

Israeli Consortium Launches Patient Sequencing Study to Uncover COVID-19 Genetic Risk Factors

Publication Authors

Apr 8, 2020 | Staff reporter

NEW YORK –A public-private consortium in Israel will collect samples and sequence genomes from thousands of COVID-19 patients in an effort to identify protective and risk-bearing genetic factors with the hopes of discovering new diagnostic and treatment methods.

Consortium partners include the Israel Ministry of Health, the Israel Innovation Authority, Sourasky (Ichilov) Medical Center, Rambam Health Care Campus, and startup company Geneyx, which offers next-generation sequencing data analysis, interpretation, reporting, and storage products and services.

According to a Geneyx spokesperson, the Israeli Innovation Authority has earmarked approximately NIS $3 million (about $838,500) for the project, while Israel-headquartered, international technology firm BATM is providing additional unspecified funding. The project’s total budget is expected to exceed $1.5 million, the spokesperson said.

“In a secure manner and with informed consent, we will gather the clinical information of COVID-19 patients hospitalized in various states of health,” Hagit Baris Feldman, director of the Genetic Institute and Genomic Center at Ichilov, said in a statement. “This is a rare opportunity to thoroughly and consistently document clinical findings of thousands of patients and sequence their whole genome.”

Dvir Dahary, chief scientist at Geneyx, added in a statement that the consortium will begin with “very rare cases … for example, healthy young people without any background diseases who have become critically ill and elderly people with only minor symptoms, and we will check what genetic specificities are related to these reactions.”

The consortium will use Illumina’s NovaSeq 6000 and Dragen Whole Genome Pipeline to sequence the COVID-19 patients, the spokesperson said. Meanwhile, Geneyx’s platform will enable documentation and standardization of sample collection and will provide genomic data analysis and storage.

The Geneyx spokesperson also noted that Amazon Web Services has donated approximately $250,000 worth of cloud computing credits to the effort.

The consortium expects the study to yield initial results by June, the spokesperson said.

Additional Articles

News

November 9, 2021

Accenture Invests in Geneyx to Expand the Use of Genetic Data for Targeted and Personalized Therapeutics and Diagnostics

Marchell Gillis

NEW YORK--(BUSINESS WIRE)--Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Geneyx Genomex Ltd. (Geneyx), an Israel-based developer of genomic analysis and interpretation software. Geneyx helps improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations.

November 10, 2021

Geneyx Genomex Closes $6.5M Seed Financing Roun

staff reporter

NEW YORK – Geneyx Genomex said Tuesday that it has closed a seed financing round worth approximately $6.5 million. Capri Ventures and Accenture Ventures led the round. The firm, which is based in Herzliya, Israel, and Foster City, California, also said that it has joined Accenture Ventures' Project Spotlight, a program that helps connect software startups with major public companies.

October 10, 2020

Geneyx Genomex Acquires NGS Sequencing Analysis Firm Toldot Genetics

staff reporter

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

April 8, 2020

Israeli Consortium Launches Patient Sequencing Study to Uncover COVID-19 Genetic Risk Factors

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

Previous
Next

November 9, 2021

Accenture Invests in Geneyx to Expand the Use of Genetic Data for Targeted and Personalized Therapeutics and Diagnostics

Marchell Gillis

NEW YORK--(BUSINESS WIRE)--Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Geneyx Genomex Ltd. (Geneyx), an Israel-based developer of genomic analysis and interpretation software. Geneyx helps improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations.

November 10, 2021

Geneyx Genomex Closes $6.5M Seed Financing Roun

staff reporter

NEW YORK – Geneyx Genomex said Tuesday that it has closed a seed financing round worth approximately $6.5 million. Capri Ventures and Accenture Ventures led the round. The firm, which is based in Herzliya, Israel, and Foster City, California, also said that it has joined Accenture Ventures' Project Spotlight, a program that helps connect software startups with major public companies.

October 10, 2020

Geneyx Genomex Acquires NGS Sequencing Analysis Firm Toldot Genetics

staff reporter

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

April 8, 2020

Israeli Consortium Launches Patient Sequencing Study to Uncover COVID-19 Genetic Risk Factors

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation